Barinthus Biotherapeutics plc American Depositary Shares (BRNS)
Stock · NASDAQ · Health Care
$0.74as of 9/18/2026
Price chart
Active signals
No technical signal is currently active for this symbol.
BRNS Signal Track Record
How signals performed across all stocks →What BRNS's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 44 | -0.3% | 50% | August 27, 2026 |
| Bollinger Band Breakdown | 20 | -3.1% | 45% | July 17, 2026 |
| Bollinger Band Breakout | 19 | -11.6% | 26% | August 18, 2026 |
| 200-Day Moving Average Touch | 5 | +4.3% | 60% | August 25, 2026 |
| Any 20-session window (baseline) | -3.1% | 42% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About BRNS
Barinthus Biotherapeutics plc, together with its subsidiaries, engages in the research, development, and commercialization of immunotherapies and vaccines in the United States and the United Kingdom. The company develops VTP-1000, an antigen-specific immune tolerance candidate, which is in Phase I clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease; and VTP-300, an immunother…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 14
- Website
- www.barinthusbio.com/
Fundamentals
- 1-day range
- $0.7192$0.79
- Market cap
- $23.08M
- P/E (trailing)
- —
- P/E (forward)
- -0.65
- EPS (trailing)
- $-1.64
- Dividend yield
- —
- Beta
- -0.31
- Avg. volume
- 86.9K
How Barinthus Biotherapeutics plc American Depositary Shares Makes Money
Where the revenue actually goes — FY2024 annual results
Source: 10-K filed Mar 20, 2025 · via SEC EDGAR / Finnhub
Forecasts
1 analyst ratings
Barinthus Biotherapeutics plc American Depositary Shares Competitors
Chosen by industry and closest market cap.
- BRNSBarinthus Biotherapeutics plc American Depositary Shares$0.74▲ 0.00%Market cap $23.08MP/E —$0.512$1.83
- TVRDTvardi Therapeutics Inc. Common Stock$1.01▼ 5.61%Market cap $23.02MP/E —$0.93$7.23
- OBXObsidian Therapeutics Inc. Common Stock$11.77▼ 3.52%Market cap $22.74MP/E —$11.79$49.97
- IGCIGC Pharma Inc. Common Stock$0.25▲ 0.00%Market cap $23.94MP/E —$0.235$0.4508
- TXMDTherapeuticsMD Inc. Common Stock$1.9▼ 1.55%Market cap $24.19MP/E 135.01$1.03$2.95
- CALCCalciMedica Inc. Common Stock$1.04▼ 3.70%Market cap $21.88MP/E —$1.27$36
- LGVNLongeveron Inc. Class A Common Stock$1.39▼ 7.33%Market cap $24.44MP/E —$1.69$12.3
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| BRNS Barinthus Biotherapeutics plc American Depositary Shares | $23.08M | — | $0.74 | ▲ 0.00% | $0.512$1.83 |
| TVRD Tvardi Therapeutics Inc. Common Stock | $23.02M | — | $1.01 | ▼ 5.61% | $0.93$7.23 |
| OBX Obsidian Therapeutics Inc. Common Stock | $22.74M | — | $11.77 | ▼ 3.52% | $11.79$49.97 |
| IGC IGC Pharma Inc. Common Stock | $23.94M | — | $0.25 | ▲ 0.00% | $0.235$0.4508 |
| TXMD TherapeuticsMD Inc. Common Stock | $24.19M | 135.01 | $1.9 | ▼ 1.55% | $1.03$2.95 |
| CALC CalciMedica Inc. Common Stock | $21.88M | — | $1.04 | ▼ 3.70% | $1.27$36 |
| LGVN Longeveron Inc. Class A Common Stock | $24.44M | — | $1.39 | ▼ 7.33% | $1.69$12.3 |
P/E shows — for peers not currently carrying a live signal of their own.
Institutional Ownership
March 31, 2026
- Total shares held
- 9.30M
- Total value held
- $7.89M
- Institutional holders
- 14
- Unknown5.20M
- Unknown1.42M
- Unknown1.24M
- Unknown642.2K
- Unknown159.5K
- Unknown151.0K
- Unknown122.2K
- Unknown119.0K
- Unknown106.0K
- Unknown73.2K
See the full, filterable feed with live charts on the MarketWall dashboard.